A
AN1
vs
S
S&P/ASX 300
Over the past 12 months, AN1 has underperformed S&P/ASX 300, delivering a return of -38% compared to the S&P/ASX 300's +6% growth.
Stocks Performance
AN1 vs S&P/ASX 300
Performance Gap
AN1 vs S&P/ASX 300
Performance By Year
AN1 vs S&P/ASX 300
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Anagenics Ltd
Glance View
Anagenics Ltd. operates as a biotechnology company, which engages in the development and marketing of therapies and diagnostic tests for inflammatory and fibrotic diseases, cancer, ischemic diseases of the heart, and hair loss. The company is headquartered in Sydney, New South Wales. The company went IPO on 2005-12-09. The principal activities of the Company include the development, distribution and sale of health, beauty and wellness products (Consumer health). The firm through its wholly owned subsidiary Advangen Pty Ltd, develops, manufactures, markets, distributes to retailers, and sells its anti-aging products globally, with its FGF5 inhibitor, hair health and hair growth products. The flagship anti-aging hair care range, marketed as evolis, Advangen Jo-Ju, and Lexilis brands are sold in Australia, Japan, and the United States of America. The Company’s subsidiary is BLC Cosmetics Pty Limited, which is the distributor of premium Australian and international beauty and wellness brands, primarily to salons and spas.